<DOC>
	<DOCNO>NCT01759238</DOCNO>
	<brief_summary>This study try evaluate role chemoradiation capecitabine bevacizumab oligometastatic patient neither progressive resectable chemotherapy .</brief_summary>
	<brief_title>Chemoradiotherapy Patients With Oligometastatic Colorectal Cancer</brief_title>
	<detailed_description>Combining chemoradiation antiangiogenic agent strong biological rationale , preclinical study consistently show increase radiosensitization combine treatment . It well describe hypoxia HIF-1 expression associate low radiation response progression solid tumor . Radiation induce transient tumor hypoxia , turn stimulates VEGF production VEGFR-2 expression may also serve paracrine proliferative stimulus promote out-of-field growth . The combination radiotherapy antiangiogenic agent ( e.g . bevacizumab ) thus offer potential enhance effect radiation , avoid spread disease . Furthermore , target tumor vasculature improve delivery cytotoxic drug ( e.g . capecitabine ) lead increase efficacy chemoradiation . Combination cytotoxic drug could additionally limit treatment-induced hypoxia ( Senan Smit 2007 ; Mazeron , Anderson et al . 2011 ) .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Patients histologically confirm diagnosis stage IV ( UICC ) colorectal cancer 2 . Oligometastatic disease , define least one measureable lesion size &gt; 1cm ( RECIST v1.1 ) maximum 3 site 5 lesion suitable radiotherapy accord dose constraint normal tissue 3 . Patients neither progressive resectable 36 month first line chemotherapy ( combination chemotherapy , least chemodoublet ) bevacizumab 4. maximum treatment interruption induction therapy 6 week 5 . ECOG performance status ≤ 1 6 . Life expectancy &gt; 3 month 7 . Age ≥ 18 year 8 . Haematologic function : ANC ≥ 1.5 x 109/L , platelet ≥ 75 x109/L 9 . INR &lt; 1.5 within 7 day prior start study treatment . aPTT &lt; 1.5 ULN within 7 day prior start study treatment 10. adequate liver function measure serum transaminase ( AST &amp; ALT ) ≤ 5 x ULN total bilirubin ≤1.5 x ULN 11. adequate renal function : serum creatinine ≤ 1.5 x ULN 12. sign , write informed consent 13. ability swallow tablet 1. treatment investigational agent , participation another clinical trial within 30 day prior enter study 2. prior radiotherapy metastatic lesion ( prior radiotherapy primary tumor allow follow complete resection sign local recurrence time enrolment ) 3 . Pre history evidence upon physical/neurological examination CNS disease ( unrelated cancer ) ( unless adequately treat standard medical therapy ) e.g . uncontrolled seizure 4. fertile woman ( &lt; 2 year last menstruation ) woman childbearing potential unwilling unable use effective mean contraception ( oral contraceptive , intrauterine contraceptive device , barrier method contraception conjunction spermicidal gel surgically sterile ) 5. pregnancy lactation 6 . Positive serum pregnancy test within 7 day start study treatment premenopausal woman woman &lt; 2 year onset menopause . Note : negative test reconfirm urine test , 7day window exceed . 7 . Past current history ( within last 2 year prior treatment start ) malignancies except metastatic colorectal cancer ( patient curatively treat basal squamous cell carcinoma skin situ carcinoma cervix eligible ) . 8 . Known DPDinsufficiency 9 . Active inflammatory bowel disease bowel disease cause chronic diarrhea ( define &gt; 4 loose stool per day ) 10 . Serious , nonhealing wound , ulcer bone fracture . 11 . Evidence bleed diathesis coagulopathy . 12 . Urine dipstick proteinuria &gt; 2+ . If urine dipstick 2+ , 24hour urine must demonstrate 1 g protein 24 hour patient eligible . 13 . Major surgical procedure , open biopsy significant traumatic injury within 28 day prior first treatment study medication . 14 . Clinically significant cardiovascular disease , example CVA , myocardial infarction ( £ 12 month treatment start ) , unstable angina pectoris , NYHA Class II CHF , arrhythmia require medication , uncontrolled hypertension . 15 . Evidence disease , metabolic dysfunction , physical examination find laboratory find give reasonable suspicion disease condition contraindicate use investigational drug put patient high risk treatmentrelated complication . 16 . Concomitant therapy sorivudin chemical analogue like brivudin 17 . Known hypersensitivity contraindication drug use trial ( eg : capecitabine , bevacizumab ) 18 . Inability unwillingness comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>metastasis</keyword>
	<keyword>non resectable</keyword>
	<keyword>chemoradiation</keyword>
</DOC>